Part 1: The ASAM Treatment of Opioid Use Disorder Course
The ASAM Treatment of Opioid Use Disorder Course
Part 1: 8-Hour
This 8-hour on-demand course provides required* education to qualify for the waiver to prescribe buprenorphine in an office-based setting and covers essential information for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD). The course covers the latest information on medications and treatments for OUD.
This course is fully on-demand and can be completed at your own pace. The flow of this on-demand course uses a mix of didactic materials, case studies, learning activities, and assessments broken into modules.
*NPs, PAs, CNMs, CRNAs, and other CNSs are required to complete no less than 24 hours of training. ASAM offers 24 hour packages for free. Click here for more information. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
The target audience for this introductory course includes:
- NPs, PAs, CNMS, CRNAs, and other CNSs who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
- Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorder.
This activity addresses the following ACGME competencies: Patient Care, Medical Knowledge, and Practice-Based Learning.
Upon completion, learners will be able to:
- Identify, assess, and diagnose patients with opioid use disorder while considering severity, chronicity, individual characteristics, and psychiatric and medical comorbidities
- Develop an individualized, patient-centered treatment plan, including negotiating treatment goals by evaluating appropriate medication- and psychosocial-based treatment options
- Monitor progress and modify treatment plans based on patient needs and progress toward treatment goals
- Implement best practices for office systems, including team-based care, to support treatment with medications for opioid use disorder
- Examine misconceptions, stigma, and complexities (bioethical, social, clinical, public health) associated with opioid use disorder and the use of medications to treat opioid use disorder
*Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Refunds & Cancellations
All ASAM e-Learning Center refund requests must be made in writing to Education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 06/30/2024
This content has been made available in part by a small unrestricted educational grant from Indivior, Inc. No input or influence from Indivior, was included in the development of the educational content. As an ACCME Provider, ASAM follows the ACCME Standards for Integrity and Independence for Accredited Continuing Education stating that owners and employees of ineligible companies are excluded from participating as planners or faculty, and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.
- Make sure your pop-up blocker is turned off and you are not in private browsing mode.
- Click the Contents tab and select Complete Course Overview. A new window will appear. After viewing the entire module, return to the Contents tab and begin Module 1. You must complete all five modules to claim credit.
- For AANP CE Credit: Learners will be given an access code at the end of Part 2 that will unlock the evaluation and certificate in AANP's CE Center. Please continue to Part 2 by returning to your Dashboard.
- For AAPA and other credits, click Complete Course Evaluation to answer evaluation questions. Scroll down on all questions as there are answers that expand past the size of the window. Submit the evaluation (the next box should activate, and the evaluation box should turn green with a white check mark).
- Click Claim Credits in the box titled Claim Credits & Certificate. Choose the type of credit needed and click submit. Click the button View/Print Certificate to save or print your certificate. If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your transcript (found in the Dashboard).
If you have are experiencing any log in issues, cannot access a course, need assistance claiming credit, or have other questions or concerns, please e-mail Education@asam.org for assistance.
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Daniel P. Alford
MD, MPH, FACP, DFASAM
Daniel Alford, MD, MPH, FACP, DFASAM is a Professor of Medicine and Associate Dean of Continuing Medical Education at Boston University School of Medicine (BUSM). He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. He is the Medical Director of the CDC-funded Boston Sustainable Models for unhealthy Alcohol use ReducTion (B SMART) and the HRSA funded SBIRT And FASD Education, Support and Treatment (SAFEST) Choice programs.
No relevant financial disclosures
MD, MTS, FASAM
Jeffrey DeVido, MD, MTS, FASAM earned a Masters in Theological Studies from Harvard Divinity School, completed his medical schooling at Columbia University College of Physicians and Surgeons, and adult psychiatry and addiction psychiatry training at Massachusetts General/McLean Hospitals. In 2013, Dr. DeVido joined the faculty of UCSF as an assistant professor working in consultation-liaison psychiatry at the Parnassus Medical Center, where he provided psychiatric evaluation and management of patients presenting to the emergency room and medical/surgical/intensive care units with co-occurring mental and medical illnesses. He is a member of the board of directors of the American Academy of Addiction Psychiatry. He sits on the American Psychiatric Association’s Council on Addictions, and he remains on faculty at UCSF. He holds board certification in adult psychiatry, addiction psychiatry, and addiction medicine. He has published on a wide range of topics, including medication for addiction treatment and management of substance use disorders in pregnancy. He recently joined the Department of Health and Human Services, Behavioral Health and Recovery Services in Marin County, CA, as the Chief of Addiction Services.
Disclosures - Does Disclose:
- Phillip Morris/Altria: Equity shareholder from inheritance
- Merck Co/Phillip Morris/Altria: Equity shareholder from inheritance
PA-C, MPAS, MPH
Debra R. Newman, PA-C, MPAS, MPH is a Treatment Provider for Adult Drug/Mental Health Treatment Courts in Santa Fe County, New Mexico. She has worked in detox/residential treatment, outpatient addiction medicine, and adult psychiatry. Her passion for addiction medicine began with her association with Project ECHO in 2008. While employed at an FQHC in northern NM in a region historically plagued with the highest per capita heroin death rate in the nation, Debra worked under an addiction medicine psychiatrist and several family practice physicians waivered to prescribe buprenorphine. For over four years, she managed over 200 buprenorphine patients monthly, as the only full-time provider for these patients, while also carrying a caseload of HCV and chronic pain patients. She participates with PCSS Exchange and is a PCSS mentor. She is currently the Assistant Editor for ASAM Weekly.
No relevant financial disclosures
Dr. Paul Earley has been an Addiction Medicine Physician for 36 years. He treats all types of addictive disorders and specializes in the assessment and treatment of health care professionals. As a therapist, he works with patients already in recovery, providing long-term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards. Dr. Earley is a Distinguished Fellow of ASAM and has been on the board of ASAM for over 20 years in several capacities. He has been the Medical Director of two nationally acclaimed addiction programs specializing in healthcare professionals who suffer from addiction illnesses. Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia in the U.S. With Earley Consultancy, LLC, he works with numerous treatment facilities, providing training in cohesive care, treatment effectiveness, and staff development.
Yngvild K. Olsen
MD, MPH, DFASAM
Yngvild K. Olsen, MD, MPH, DFASAM graduated from Harvard Medical School in 1997, from the residency training program in internal medicine at Boston Medical Center in 2000, and from the Fellowship in General Internal Medicine at the Johns Hopkins School of Medicine in 2001. Dr. Olsen also serves as the Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services in Baltimore City. Dr. Olsen currently serves as Vice President of the American Society of Addiction Medicine and is a member of the Public Policy Committee. She is the Immediate Past President of the Maryland Society of Addiction Medicine, Immediate Past President of the Maryland Association for the Treatment of Opioid Dependence, and a Board member of the National Council on Alcoholism and Drug Dependence-MD (NCADD-MD).
No relevant financial disclosures
MD, MBA, DFASAM
Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. Brian is currently a Director at Large for the American Society of Addiction Medicine (ASAM) and will assume the position of President-Elect this April 2021. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Addiction Treatment Starts Here programs through the Center for Care Innovations, focused on increasing the delivery of Medications for Addiction Treatment in California’s community health centers. He is the PI of two MAT Access Points projects funded by the Sierra Health Foundation, a co-PI of a TRDRP funded smoking cessation implementation project, and a co-investigator on NIDA, NIAAA, and PCORI funded addiction related implementation science grants managed through RAND. He is a member of the Motivational Interviewing Network of Trainers and regularly conducts motivational interviewing trainings throughout the United States. He is a Volunteer Assistant Clinical Professor of Addiction Medicine in the Department of Family Medicine at the UCLA David Geffen School of Medicine. He additionally serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry examination writing committee.
Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a UCLA - Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed a fellowship program in addiction psychiatry at New York University School of Medicine. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry. Brian is a former National President of the American Medical Student Association.
No relevant financial disclosures
Edwin A. Salsitz
Dr. Edwin Salsitz has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM) and the Board of Internal Medicine and Pulmonary Disease.
No relevant financial disclosures
Margaret Jarvism MD, DFASAM finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.
Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.
Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.
Kristin Smith graduated from St. John Fisher’s FNP/DNP program in May 2013. She is a staff clinician and the Program Director of a Nurse Practitioner (NP) Residency Program at Highland Family Medicine, where she provides Medication Assisted Treatment (MATx) in both dedicated suboxone clinics as well as integrated primary care settings. Dr. Smith is also a certified American Academy of HIV Medicine Specialist with experience providing HIV care and Pre/Post-Exposure prophylaxis. Prior to transitioning to her current role, she served as the Clinical Director of an Opioid Overdose Prevention Program, where she became passionate about harm reduction while providing community training on Naloxone, teaching safe injection practices, and providing needle exchange services in collaboration with a team of individuals through Trillium Health.
No relevant financial disclosures
Kyle M. Kampman
Kyle Kampman, MD, FASAM graduated from Northwestern University in 1981 and Tulane University School of Medicine in 1985. He interned at the National Naval Medical Center at Bethesda, Maryland, and served as a medical officer in the United States Navy from 1985 until 1990. He came to the University of Pennsylvania and served as a resident in Psychiatry from 1990 until 1993. He then completed a fellowship in Addiction Psychiatry. In 1994 he joined the faculty in the Department of Psychiatry as an assistant professor. He was promoted to associate professor in 2003 and to professor in 2012. Dr. Kampman has had extensive experience in the treatment of alcohol, cocaine, and opioid dependence. He chaired the committee that wrote the ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. He has conducted a number of trials testing medications for the treatment of cocaine, alcohol, and opioid dependence and is a recognized authority on the cocaine withdrawal syndrome. In addition to research, he works at the Addiction Recovery Unit of the Philadelphia VA Medical Center, where he continues to treat cocaine, alcohol, and opioid-dependent patients with both medications and psychotherapy.
Bernard Stuetz, PA-C, MA is the Past President of the Society of Physician Assistants in Addiction Medicine and currently acting as Chief Delegate to the American Academy of PAs (AAPA) House of Delegates (HOD). He is also the Director for Federal Affairs. He has been a delegate to the AAPA HOD for 31 years. He was a member of the AAPA Recertification Committee in 2012, during which he recommended changes to the ten-year cycle requirements. As a delegate in the AAPA HOD, he was the lead advocate to change the re-certification cycle from six to ten years. He was the first PA to work in the White House on Health Care Policy from 1993 to 1995. Having practiced Addiction Medicine for 25 years, Mr. Stuetz currently works in an OTP and Buprenorphine practice.
No relevant financial disclosures
MD, MPH, FASAM
Laura Kehoe, MD, MPH, FASAM is the medical director of the Massachusetts General Hospital Substance Use Disorder Bridge Clinic, an immediate access, low barrier transitional clinic, which is a component of MGH’s Substance Use Disorder Initiative. She is an Assistant Professor of Medicine at Harvard Medical School. She received her A.B. from Washington University in St. Louis, her MD from Tufts University School of Medicine, and her MPH from Boston University School of Public Health. She completed her residency in internal medicine at Massachusetts General Hospital and is board certified in both internal medicine and addiction medicine. She has cared for patients in primary care, inpatient, residential, and outpatient addiction treatment settings and as a medical director at a Boston area methadone maintenance treatment program.
Matt Tierney, APRN is a Nurse Practitioner and a Clinical Professor at the UCSF School of Nursing. He also serves as Clinical Director of Substance Use Treatment and Education for the Office of Population Health at UCSF Health. The focus of his career has been on improving essential addiction treatment delivery locally, regionally, and nationally. He is a Fellow of the American Academy of Nursing, where he serves on the Expert Panel on Psychiatric-Mental Health and Substance Use. Matt is also President-Elect of the American Psychiatric Nurses Association and represents APNA as a sponsoring member of the National Academies of Science Engineering and Medicine's Forum of Mental Health and Substance Use Disorders. He is an ASAM member who has been teaching waiver training courses since 2008. He has treated over 1,600 patients with buprenorphine and has worked in licensed Opiate Treatment programs providing all three FDA-approved medications for OUD treatment.
No relevant financial disclosures
Kelly Kleinert, MD is an Assistant Clinical Professor of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons, board-certified in Psychiatry and Addiction Medicine. She is Associate Unit Director on 4 South, the inpatient unit of the Washington Heights Community Service at New York State Psychiatric Institute, where she works with patients with severe mental illness and often concomitant substance use disorders. Previously, she worked at Janian Medical Care, a nonprofit psychiatric and primary medical care organization in New York City, caring for individuals with co-occurring psychiatric and substance use disorders on a homeless outreach team and on an Assertive Community Treatment (ACT) team. Dr. Kleinert graduated from Columbia University Vagelos College of Physician and Surgeons and completed residency in General Psychiatry at New York University/Bellevue Hospital. Following residency, she returned to Columbia to complete a fellowship in Public Psychiatry.
Disclosures - None
J. Deanna Wilson
Deanna Wilson, MD, MPH Assistant Professor of Medicine and Pediatrics at the University of Pittsburgh School of Medicine. She received her MD from Yale University School of Medicine and trained in internal medicine and pediatrics at the Johns Hopkins University School of Medicine. She completed additional subspecialty training in both adolescent and addiction medicine also at Johns Hopkins. She currently sees patients at UPMC’s Center for Opioid Recovery, a Pennsylvania Center of Excellence. She provides inpatient addiction medicine consultation to patients hospitalized at UPMC Presbyterian Hospital and is Medical Director for the Center for Adolescent and Young Adult Recovery and Empowerment. She has expertise in integrating harm reduction, substance use treatment, and primary care into clinical practice. Her current research interests are in the design and evaluation of interventions to engage and retain hospitalized young adults who inject drugs into substance use treatment. She leverages health services research, implementation science, and community engaged methods to improve health equity for vulnerable populations who use substances.
MD, FACEP, FACMT, FASAM
Lewis Nelson, MD, FACEP, FACMT, FASAM is Professor and Chair of the Department of Emergency Medicine and Chief of the Division of Medical Toxicology at Rutgers New Jersey Medical School in Newark, NJ. He is a member of the Board of Directors of the American Board of Emergency Medicine and a Past-President of the American College of Medical Toxicology. He remains actively involved with the CDC, FDA, DHS, and several professional medical organizations, including ASAM. Dr. Nelson is an editor of the textbook Goldfrank’s Toxicologic Emergencies and on the editorial boards of several journals.
Disclosures - None
Alain H. Litwin
Alain Litwin, MD, MPH is Vice Chair of Academics and Research and Professor of Medicine at Greenville Health System, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he is launching a Center for Addiction and Prevention Research. He is board certified in internal medicine and addiction medicine, and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx. With funding from NIH, PCORI, CMS, CDC, AHRQ, the Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of HCV care, and on advocating for increasing access to effective care for all HCV-infected patients.
Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with the New York City Department of Health and Mental Hygiene, New York State Department of Health, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment, American Association for the Treatment of Opioid Dependence, and the American Society of Addiction Medicine. Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).
JoAn Laes, MD is an addiction medicine physician and consulting medical toxicologist. Her focus is inpatient addiction medicine and toxicology consultation, and outpatient treatment of opioid and other substance use disorders. She is an owner at Twin Cities Toxicology, providing consultation, medical directorship, and expert opinion in the fields of addiction medicine and medical toxicology. She is board-certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed an internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota. She has spoken nationally on the subjects of addiction medicine and toxicology.
Michelle R. Lofwall
Michelle R. Lofwall completed residency training in Psychiatry and a clinical research fellowship in behavioral pharmacology at Johns Hopkins University. She now is an Associate Professor of Behavioral Science and Psychiatry in the Center on Drug and Alcohol Research at the University of Kentucky. She is a strong addiction treatment advocate and has an active outpatient addiction treatment practice. She also teaches residents, medical students, and other allied health professionals about treatment of substance use disorders.
She spends the majority of her time engaged in clinical research aimed at improving substance abuse treatment and better understanding the behavioral pharmacology of drugs of abuse. Dr. Lofwall is the immediate past President of the Kentucky Chapter of the American Society of Addiction Medicine, Editor of the American Academy of Addiction Psychiatry newsletter, and member of the Kentucky Governor's state prescription monitoring program Advisory Council.
MD, DFAPA, FASAM
Carla Marienfeld, MD, is a board-certified addiction psychiatrist and Clinical Professor at the University of California, San Diego who supports recovery in an evidence based, harm-reduction approach through therapy, motivational interviewing, and medication treatment. Her research involves analysis of electronic medical record data for individuals with substance use disorders. She has authored or co-authored over 35 peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston.
No Relevant Financial Disclosures
Elizabeth M. Salisbury-Afshar
MD, MPH, FAAFP, FACPM, DFASAM
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM is the Director of the Center for Addiction Research and Effective Solutions at the American Institute for Research, a nonprofit social and behavioral sciences research organization. Dr. Salisbury-Afshar is board certified in family medicine, preventive medicine/public health and addiction medicine and her expertise lies at the intersection of these fields. Past roles include serving as the Medical Director of Behavioral Health Systems Baltimore, a quasi-public entity that oversees all publicly funded addiction and mental health treatment and as the Medical Director of Behavioral Health at the Chicago Department of Public Health. She has over ten years of experience working clinically in federally qualified health centers- providing direct patient care in both primary care and addiction medicine. She previously served as the Medical Director of Heartland Alliance Health, a healthcare for the homeless provider in Chicago, and she continues to work in this clinic on a part-time basis and provides primary care and addiction treatment services. Dr. Salisbury-Afshar received her Medical Degree from Rush University Medical College and her Master’s in Public Health from Johns Hopkins Bloomberg School of Public Health.
No relevant financial disclosures.
Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases, and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System, where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from the University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD).
Sharon Stancliff, MD is Associate Medical Director for Harm Reduction in Health Care at the AIDS Institute, New York State Department of Health and she is a staff physician at Project Renewal where she prescribes buprenorphine an FQHC in a men’s shelter. Dr. Stancliff has been working with people who use drugs since 1990 including provision of primary care, drug treatment, HIV care and syringe access. She has been the Medical Director of a Community Health Center, an Opioid Treatment Program and the Harm Reduction Coalition. Her current focus is on opioid overdose prevention through expanding access to buprenorphine in primary care and in less traditional settings such as syringe access programs as well as expanding access to naloxone. She has spoken and provided technical assistance these topics nationally and internationally as well as publishing in books and peer reviewed journal. She is an active member of the American Society of Addiction Medicine. She maintains board certification in Family Medicine, and in Addiction Medicine.
Disclosures - None
Alaina R. Steck
Alaina R. Steck, MD is an Assistant Professor of Emergency Medicine at Grady Memorial Hospital, in the Emory Department of Emergency Medicine. She completed her residency training in Emergency Medicine at Boston Medical Center in Boston, MA and her fellowship in Medical Toxicology at the Emory / Centers for Disease Control and Prevention Combined Fellowship in Medical Toxicology, followed by board certification in Addiction Medicine. She currently serves as the Medical Director of the Grady Medication-Assisted Opioid Treatment clinic, clerkship director for Medical Toxicology, Assistant Director at the Georgia Poison Center, and co-chair of the Drug Safety Task Force of the Injury Prevention Research Center at Emory.
R. Corey Waller
MD, MS, DFASAM
R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neuromolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.
Nalan Ward, MD is an associate psychiatrist in the Department of Psychiatry at the Massachusetts General Hospital (MGH) and an Assistant Professor in Psychiatry at Harvard Medical School (HMS). She completed psychiatry residency and addiction psychiatry fellowship at the Boston University Medical Center. She joined MGH Department of Psychiatry in 2005 as the Medical Director of the Outpatient Addiction Services. Dr.Ward is a co-chair of the MGH Substance Use Disorders Education Committee and a member at MGH Opioid Task Force Steering Committee and the Academy at HMS. Dr. Ward is a medical consultant for the Massachusetts Department of Public Health, Bureau of Substance Addiction Services for Quality Assurance and Licensing. Dr. Ward is a Course Director for Buprenorphine Waiver Training (PCSS-MAT). She is the lead addiction psychiatry consultant for the Partners Healthcare, Center for Population Health Management Behavioral Health Consults. Previously, she worked as the Medical Director of the Methadone Maintenance Program for North Charles Institute for Addictions from 2002-2009.
Dr. Ward has presented locally and nationally. She has authored and co-authored more than 19 articles and 4 book chapters. Her topic of interests is treatment of opioid use disorders, comorbid pain conditions, clinical innovations in increasing access to addictions care, clinical education of trainees and professional academic development in the field of addiction psychiatry. Dr. Ward is board certified in adult and addiction psychiatry.
Timothy J. Wiegand
MD, FACMT, FAACT, DFASAM
Timothy Wiegand, MD, FACMT, FAACT, DFASAM is the Director of Toxicology for the University of Rochester Medical Center and an Associate Professor of Emergency Medicine with secondary appointment in Public Health Sciences. He holds Board Certification in Medical Toxicology and Addiction Medicine and has an active clinical practice through the Department of Emergency Medicine running the Toxicology Consult Service, which serves as the foundation for the toxicology/addiction rotation at URMC. Dr Wiegand is also the Associate Fellowship Director for the URMC Combined Addiction Medicine Fellowship and he serves as Medical Director for Huther Doyle a Rochester, NY area outpatient addiction treatment program. Dr. Wiegand is active professionally with a variety and he serves on the Board of Directors for the American College of Medical Toxicology, the American Society of Addiction Medicine Board as an At-Large Director and is President Elect of the New York Society of Addiction Medicine. Dr. Wiegand also serves on the Board of the Medical Toxicology Foundation which has as a priority to support research, innovation and education related to the interface of toxicology and addiction in particular related to the opioid and overdose epidemic.
Dr. Wiegand lectures on a variety of toxicology and addiction subjects at state and national events as well as internationally including the treatment of drug and alcohol withdrawal, on the use of buprenorphine to stabilize opioid withdrawal in Emergency Department and hospital settings, and on the treatment of pain and perioperative management for patients on buprenorphine and methadone.
DO, FOAAM, FASAM
Stephen Wyatt, DO, FOAAM, FASAM is a Board Certified Psychiatrist with added subspecialty certification in Addiction Psychiatry. He currently serves as the Medical Director of Addiction Medicine for Carolinas HealthCare System, CHS. He is a CHS Professor of Psychiatry and an adjunct clinical faculty member of the University of North Carolina. Dr. Wyatt practiced Emergency Medicine in Michigan for 13 years before entering psychiatry training; finishing in an addiction psychiatry clinical research fellowship at the Yale School of Medicine. He is the current Chairman of the NC Psychiatric Association. Addiction Psychiatry Committee and the Vice Chair of the Coalition on Physician Education in Substance Use Disorders a national organization focused on addiction medicine medical school education. He participated in the writing of the ASAM Clinical Guidelines for Office Based Opioid Treatment and is a Clinical Expert for the SAMHSA funded Provider Clinical Support System for Medication Assisted Treatment.
DO, MCR, DFASAM
Melissa Weimer, DO, MCR, DFASAM is board-certified in Internal Medicine and Addiction Medicine and an Assistant Professor of Medicine at Yale University School of Medicine. At Yale, she also serves as the Medical Director of the Yale Addiction Medicine Consult Service and Associate Program Director of the Addiction Medicine Fellowship Program. Dr. Weimer has a clinical and research focus on expanding access to treatment for patients with substance use disorders, particularly in the hospital setting. She also has fellowship training and years of experience in the management of complex pain, particularly for patients with concomitant opioid use disorders.
No relevant financial disclosures
CME, CE, CEU and Other Credit Types
American Association of Nurse Practitioners (AANP)
This activity is approved for 8.0 contact hour(s) of continuing education (which includes 6.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21075052. This activity was planned in accordance with AANP Accreditation Standards and Policies
American Academy of Physician Assistants (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. Approval is valid from 6/10/2021 to 12/31/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200882.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA / AAFP Equivalency
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification
American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.
American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.
American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.